Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...
Sep 17, 2012
0
0